Novel CAR constructs are being developed to specifically target EBV-related antigens such as LMP1 and LMP2, which are selectively expressed on the surface of EBV-transformed cells, allowing for more direct and virus-specific tumor killing (62, 63). The gene discussed is PSMB9; the disease is neoplasm.